

Selected Regulatory Considerations for Cancer Immunotherapeutic Combinations: Contribution of Individual Components to Effect of Combination

Addressing Resistance in the Development of Cancer Immune Modulator Therapeutics

Session 5: Criteria to Assess Cancer Immunotherapy Combinations in Early-Phase Clinical Trials

Marc Theoret, MD

Deputy Director, Oncology Center of Excellence

U.S. Food and Drug Administration


November 15, 2022

#### Disclosures



- I have no financial conflicts of interest
- I will not discuss off-label use
- Views expressed here are those of the presenter and not necessarily those of the U.S. FDA.

#### **Treatment Landscape: ICI\* Approvals**




#### 900 892.2 1,100 -Cell therapy **CD73** Combo. CD20 22 Average planned Number of PD1/PDL1 trials started per year - 800 22 1,000 Mono. Chemoradio 900 Radiotherapy 700 154 236 800 PARP 600 107 700 enrolment per trial per 500 TIGIT 600 60 704 807 982 830 Chemotherapy **VEGF/R** IL2/R 788 558 500 -400 39 381.1 LAG3 590 55 400 - 300 359 Cancer vaccine 214.7 300 184.5 190.1 EGFR 164.8 160.5 - 200 142.4 141.8 TAA 45 129.2 200 -**TLRs** 208 CTLA-4 year HER 147.3 142.5 110.5 - 100 134.9 120.3 100 121.4 537 48 72 190 184 70 140 0 0 2014 2015 2016 2017 2018 2019 2020 2021

#### Landscape: PD-(L)1 Inhibitor Combination Regimens


Upadhaya et al., Nat Rev Drug Discov, 2022

FDA

#### **Timeline of ICI\* Approvals: Combinations**



#### **Immunotherapy: Patterns of Response**



Adapted from Wolchok, 2009, Clin Cancer Res

## Analyses of Treatment Beyond Progression (TBP) with Anti-PD-1 mAbs



		N	PD, n	TBP, n (%)	Reference Tumor Burden	TBP Responders <sup>d</sup>	
	Disease					% of All Pts	% of TBP Pts
George 2016	RCC	168	154	62 (37%) <sup>a</sup>	Baseline	7	19
Escudier 2017	RCC	406	316	153 (42%) <sup>b</sup>	PD	5	13
Kazandijan 2017	NSCLC	535	420	121 (23%) <sup>c</sup>	Baseline	2	8
Long 2017	Mel	526	306	85 (16%) <sup>b</sup>	Baseline	5	28
Beaver 2018	Mel	2624	1361	692 (26%) <sup>c</sup>	PD	4	14

<sup>a</sup> TBP at least 4 weeks

<sup>b</sup> TBP at least 6 weeks


<sup>c</sup> Any TBP

<sup>d</sup> ≥30% Decrease in Target Lesion Tumor Burden

#### Anti-PD-(L)1 mAbs – Overall Survival by Best Overall Response per RECIST 1.1 and iRECIST

FDA





Mulkey, Theoret, et al., 2020, J Immunother Cancer

## Major Principles Discussed -- anti-PD-(L)1 mAb Refractory / Resistant Population



- Adequate Exposure to anti-PD-(L)1 mAb by Specifying Dose and Length of anti-PD-(L)1 Therapy Prior to Disease Progression
- Best Response to anti-PD-(L)1 mAb Prior to Disease Progression
- Confirmation of Disease Progression (including the timing of confirmation)
- Minimize Likelihood of Late Response to an anti-PD-(L)1 mAb or with Reexposure of anti-PD-(L)1 mAb

Kluger et al., 2019, J Immunother Cancer FOCR, 2019 Annual Meeting, Session 2 White Paper , <u>https://www.focr.org/sites/default/files/pdf/Panel-2\_Combo\_IO\_Tx\_2019AM.pdf</u>.

#### **Contribution of Individual Products to Treatment Effect of Combination Use**

- C/W Requirement for Demonstrating Contributions of Components of Fixed-Drug Combinations (21 CFR 300.50 *Fixed-combination prescription drugs for humans*)
  - Two or more drugs may be combined "...when each component makes a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy"
- "The purpose of conducting clinical investigations of a drug is to distinguish the effect of a drug from other influences, such as spontaneous change in the course of the disease, placebo effect, or biased observation." (21 CFR 314.126 Adequate and well-controlled studies)
- FDA "is required to exercise its scientific judgment to determine the kind and quantity of data and information an applicant is required to provide for a particular drug to meet the statutory standards" for safety and effectiveness (21 CFR 314.105(c))
- FDA "has determined that it is appropriate to exercise the broadest flexibility in applying the statutory standards, while preserving appropriate guarantees for safety and effectiveness" (21 CFR 312, subpart E, Drugs intended to Treat Life-threatening and Severely-debilitating Illnesses)


#### Demonstrating Contribution of Individual Drugs to Effect (COE) of Novel Combination



- Randomized, Controlled Factorial Design for COE When Feasible
- External Data<sup>1</sup> to Demonstrate COE May Be Supported By
  - Strong Biological Rationale
  - Natural history of the disease is highly predictable
  - Safety and Efficacy Demonstrated in Other Indications
  - Monotherapy Known to be Minimally Active
  - Novel Combination Has Large Magnitude of Treatment Effect
- Key Considerations
  - Source of Data
  - Suitability of Data
  - Endpoints

#### Hypothetical Examples of Contribution of Effect (COE): Multi-arm with Each Monotherapy






**Contribution of Drug B** 

# New Investigational Drug with Drug Approved in Different Indication




- Randomized Trial to Demonstrate Contribution of Components
- Greater Uncertainty With External Data Source May Preclude Use For
  - New investigational drug
  - Settings where treatment effect less reliable based on natural history
  - Novel combinations where magnitude of treatment effect is modest
- Strong Biologic Rationale And Nonclinical And/Or Early Clinical Evidence Supporting Necessity Of Each Drug May Reduce Uncertainty
  - External data from clinical trials investigating the previously approved<sup>1</sup> drug(s) as monotherapy in the same indication as for the novel combination regimen


#### **COE Examples (cont'd): Add-on Design**




FDA



Note: External Data to Support PD-(L)1 Inhibitor Monotherapy is Minimally Active



Note: External Data to Support PD-L(1) Inhibitor Monotherapy Minimally Active



Note: External Data to Support Novel Drug B Monotherapy is Minimally Active

#### **Two or More Previously Approved<sup>1</sup> Drugs**



- Randomized Trial to Demonstrate Contribution of Components
- Prior Determinations of Safety and Effectiveness May Provide Opportunity to Rely on Additional Sources of External Data, with Consideration of
  - Similarity of biologic underpinnings across diseases or clinical context of that disease
  - Strength of rationale for use of combination in a specific disease
  - Strength of external data sources demonstrating contribution of effect in other indications
  - Quality and quantity of clinical data demonstrating contribution of individual component in other indications
  - Clinical importance of the benefit with the novel combination

## Selected Take Home Points – PD-1 Inhibitor Refractory / FDA Resistance And Novel Combination Regimens

- No Formal Regulatory Definition
- Consider Impact of Definition on the Intended Patient Population
- Combination Regimen Demonstration of Contribution of Effect
- Select Endpoints That Capture the Treatment Effect
- Randomized Trials Early in Development Program
- Magnitude of Treatment Effect of the Single Agent? Combination?
- Encourage Discussing Plans to Demonstrate Contribution of Effect in Advance with With Review Division

#### Thank you



#### **Acknowledgements**

Pallavi Mishra-Kalyani Donna Rivera Raji Sridhara Rick Pazdur

#### **Contact Information:**

Marc Theoret, MD Deputy Director Oncology Center of Excellence (OCE) U.S. Food and Drug Administration Marc.Theoret@fda.hhs.gov



Follow <u>@FDAOncology</u> on Twitter Visit <u>www.fda.gov/OCE</u>

#### **Novel Combination Regimens**



#### Guidance for Industry

Codevelopment of Two or More New Investigational Drugs for Use in Combination

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

> June 2013 Clinical Medical

#### **Key Concepts**

- Nonclinical & Early Clinical Development Considerations
- Appropriate Development
  Context -Risks of
  Codevelopment
- Contribution of Components
- Trial Designs



#### **Development Program Examples – Prior Ipilimumab**



Two anti-PD-1 mAbs approved in 2014 for

 treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor

#### **Development Program Examples – Prior Ipilimumab**



**Considerations Related to Ipilimumab** 

- Ipilimumab OS Benefit / Modest Effects on ORR and PFS
- Unmet needs
- "Late effects" of ipilimumab In prior ipilimumab-exposed patients

#### Eligibility Criteria for Prior Ipilimumab in the Registration Trials:

	PN001 (Pembrolizumab)	CA209037 (Nivolumab)
# of Prior Doses	Previously treated with ≥ 2 doses	Not specified
Prior Dosage	≥3 mg/kg administered q3W	Not specified
Confirmation of Disease Progression	Confirmed progression per immune-related response criteria within 24 weeks of last dose	Progression after anti-CTLA-4 treatment – Confirmed progression not required

FDA Clinical and Statistical Reviews of Nivolumab Original BLA and Pembrolizumab Original BLA, Drugs@FDA



25

	Pembrolizumab	Nivolumab	
Intended Approval Pathway	Accelerated	Regular or Accelerated	
Trial Design/Arms	Randomized, Dose-Comparison Pembro 2 mg/kg vs. 10 mg/kg	Randomized Controlled Trial Nivolumab vs. Chemo	
Primary Endpoint(s)	ORR	ORR / OS	
Statistical Considerations	Exclude ORR <10% Comparison of ORR of 2 doses	Exclude ORR < 15% Comparison of OS	